...
首页> 外文期刊>International journal of toxicology >Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): V. A 13-week toxicity study of tripeptides-containing casein hydrolysate in male and female rats.
【24h】

Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): V. A 13-week toxicity study of tripeptides-containing casein hydrolysate in male and female rats.

机译:三肽(L-戊基-L-脯氨酰-L-脯氨酸和L-异亮氨酰-L-脯氨酰-L-脯氨酸)的毒理学潜力研究:V.含有三肽的酪蛋白水解产物对男性和女性的13周毒性研究雌性大鼠。

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of this multiple-dose toxicity study was to assess the toxicological potential of two tripeptides, L-valyl-L-prolyl-L-proline (VPP) and L-isoleucyl-L-prolyl-L-proline (IPP), when administered once daily for 91 consecutive days to rats. The test article, powdered casein hydrolysate (CH) known to contain 0.6% VPP plus IPP, was prepared using Aspergillus oryzae protease. Prior to administration to the rats by oral gavage, the test article was suspended in sterile water. Groups of 12 male and 12 female Charles River rats were administered once daily doses of 0, 40, 200, or 1000 mg of CH (0, 0.2, 1.2, or 6 mg VPP plus IPP/kg body weight [BW]). Antemortem evaluative parameters included gross observations of behavior and clinical signs; food consumption and body weight gains; ophthalmologic examinations; clinical pathology (hematology, clinical chemistry); and urinalysis. Postmortem parameters included determination of absolute and relative (to fasting body weight) organ weights and histopathological evaluation of approximately 50 organs and tissues from each animal. All rats survived until the scheduled termination of the study and no treatment-related clinical signs were observed. Food consumption was unaffected by administration of CH. All animals gained weight and there were no statistical differences between groups with respect to weight gains. There were no meaningful changes in hematological or coagulation parameters. Mid- and high-dose males (but not females) had slightly (< 2%) increased mean serum chloride concentrations, but because the difference was so small and it was observed in only one sex, the authors considered its association with CH administration to be doubtful. Urinalysis revealed the occasional presence of crystals, leukocytes, and epithelial cells in animals from all experimental groups. Similarly, ophthalmic changes (lenticular clouding) were observed in both control and dosed animals. Mean relative (to body weight) kidney weight was decreased by 8% in low-dose males and mean relative uterus weight was elevated 46% in low-dose females. Absolute organ weights were not affected. Only naturally occurring microscopic changes were observed in all groups and none could be attributed to CH administration. It was concluded that, under the conditions of these experiments, the maximally tolerated dose (MTD) and the no-observable-effect level (NOEL) for powdered CH administered once daily for 13 weeks was greater than 1000 mg/kg BW/day or greater than 6 mg of VPP plus IPP/kg BW/day. There was no evidence of target organ toxicity associated with administration of the tripeptides. This corresponds to an margin of safety (MOS) of 60 based upon current thinking regarding incorporation in food.
机译:这项多剂量毒性研究的目的是评估两种三肽L-戊基-L-脯氨酰-L-脯氨酸(VPP)和L-异亮氨酰-L-脯氨酰-L-脯氨酸(IPP)的毒理学潜力连续91天每天一次对大鼠给药。使用米曲霉蛋白酶制备测试品,即已知含有0.6%VPP和IPP的粉末状酪蛋白水解产物(CH)。在通过口管给大鼠给药之前,将测试制品悬浮在无菌水中。每天一次给每组12只雄性和12只雌性Charles River大鼠施用0、40、200或1000 mg CH(0、0.2、1.2或6 mg VPP加IPP / kg体重[BW])。事前评估参数包括对行为和临床体征的总体观察。食物消耗和体重增加;眼科检查;临床病理学(血液学,临床化学);和尿液分析。死后参数包括绝对和相对(相对于空腹体重)器官重量的确定以及每只动物的大约50个器官和组织的组织病理学评估。所有大鼠均存活直至预定的研究终止,并且未观察到与治疗有关的临床体征。食物的摄入不受CH的影响。所有动物体重增加,并且各组之间体重增加没有统计学差异。血液学或凝血参数没有有意义的变化。中剂量和高剂量男性(而非女性)的平均血清氯化物浓度略有增加(<2%),但是由于差异很小,而且仅在一种性别中观察到,因此作者认为其与CH的管理相关值得怀疑。尿液分析显示在所有实验组的动物中偶有晶体,白细胞和上皮细胞的存在。类似地,在对照动物和剂量动物中都观察到眼科变化(双突性白浊)。低剂量雄性的平均相对(相对于体重)肾脏重量减少了8%,低剂量雌性的平均相对子宫重量增加了46%。绝对器官重量不受影响。在所有组中仅观察到自然发生的微观变化,没有一个可以归因于CH的施用。结论是,在这些实验条件下,每天一次连续13周服用CH的粉状CH的最大耐受剂量(MTD)和不可观察到的效果水平(NOEL)大于1000 mg / kg BW /天或大于6毫克VPP加上IPP /千克体重/天。没有证据表明与三肽给药有关的靶器官毒性。根据目前有关掺入食品的想法,这相当于60的安全系数(MOS)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号